Video
Dr. Staskin discusses counseling patients on vibegron for OAB
Author(s):
“Patients want to see an improvement. They want a drug that obviously is efficacious and safe, where the side effects are low,” says David Staskin, MD.
Video Player is loading.
In this video, David Staskin, MD, discusses the takeaways associated with the findings from the study, “Vibegron for the treatment of patients with dry overactive bladder: A subgroup analysis from the EMPOWUR trial,” presented at the 2021 American Urological Association annual meeting. Staskin is a director of the Center for Male and Female Pelvic Health and associate professor of urology at Tufts University, Boston, Massachusetts.
Related Videos
Study results show CVAC 2.0 is safe, efficacious for wide range of kidney stones
De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
Alternative treatments and patient communication for genitourinary syndrome of menopause
Amir Patel, MD, on ureteral strictures following holmium vs TFL laser lithotripsy
Prostate cancer screening: Expert weighs in after Biden's diagnosis
Sarah Razavi, MD, discusses the physical toll of ureteroscopy on urologists
Study results affirm effectiveness of evolving prostate cancer therapies
Laura Davis, MD, on link between microplastics and bladder cancer
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
Related Content
